Jiangsu Hengrui Pharmaceuticals' independently developed Class 1 innovative drug Haskubarparib ethylamine tablets approved for new indications.

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, the company received a notice from the National Medical Products Administration approving the new indication for the company's independently developed Type 1 innovative drug, Haiqu Buparipa Ethanolamine tablets. This drug, in combination with immunosuppressive therapy, is suitable for patients aged 15 and above with newly diagnosed severe aplastic anemia (SAA). It is reported that Haiqu Buparipa Ethanolamine tablets were approved for two indications for market launch in 2021: 1. This drug is suitable for adult patients with chronic immune thrombocytopenia (ITP) who have had poor responses to previous treatments such as glucocorticoids and immunoglobulins. 2. This drug is suitable for adult patients with severe aplastic anemia (SAA) who have had poor responses to immunosuppressive therapy (IST).